Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

The requested reference [b36aa6b67cfa58ea371dff217cbcd6291b1bd394] no longer exists in our database. It has been replaced by the current reference: [fdb7cb983959af102d3e581b85199ac60ae649dd]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic Lifei Xiaoji Wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional Chinese medicine
Epistemonikos ID: 4fb9e36dca62b78b16ebe1ec8ed8faf7ecb144db
First added on: May 16, 2024